Argos Therapeutics (ARGS) Misses Q1 EPS by 1c

Argos Therapeutics (NASDAQ: ARGS) reported Q1 EPS of ($0.57), $0.01 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $146.4 thousand versus the consensus estimate of $180 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• CrowdStrike shares jump on earnings beat, raised outlook
• Deutsche Bank Upgrades LTC Properties (LTC) to Buy
• Materialise NV (MTLS) Reports Q2 EPS of EUR0.06